Understanding the Market | VIVA BIOTECH rose nearly 15% in the afternoon after reaching a strategic cooperation on AI innovative drugs with WBDE. The company recently showcased its self-developed AIDD platform
I'm LongbridgeAI, I can summarize articles.VIVA BIOTECH rose nearly 15% in the afternoon, and as of the time of publication, it was up 13.33%, trading at HKD 1.87, with a transaction volume of HKD 15.503 million. In terms of news, WBDE and VIVA BIOTECH recently reached a strategic cooperation agreement on AI innovative drugs. The two parties will leverage their advantages in chemical drugs, traditional Chinese medicine, AI, and other fields to cultivate new productive forces, empowering innovative drug research and development with AI. Additionally, they will collaborate in areas such as innovative drug layout, AI industry chain layout, AI pharmaceutical talent cultivation, and global business development. Notably, VIVA BIOTECH recently showcased its self-developed AIDD platform for the first time at the "Enchantment of Drug Discovery" launch event. China Merchants Securities previously pointed out that AI empowers the entire drug discovery platform, evolving from "AI-assisted" to "AI-driven." By the end of 2024, AIDD is expected to have participated in a total of 157 projects, with 51 cumulative clients for CADD/AIDD procurement, and projects empowered by AI generating over ten million dollars in revenue, having achieved well-known collaborations for a complete AI discovery solution in certain niche areas
According to Zhitong Finance APP, VIVA BIOTECH (01873) rose nearly 15% in the afternoon, and as of the time of writing, it was up 13.33%, trading at HKD 1.87, with a transaction volume of HKD 15.503 million.
On the news front, WBDE and VIVA BIOTECH recently reached a strategic cooperation agreement for AI innovative drugs. The two parties will leverage their advantages in chemical drugs, traditional Chinese medicine, AI, and other fields to cultivate new productive forces, empowering innovative drug research and development with AI. Additionally, they will collaborate in areas such as innovative drug layout, AI industry chain layout, AI pharmaceutical talent cultivation, and global business development.
It is worth noting that VIVA BIOTECH recently showcased its self-developed AIDD platform for the first time at the "Enchantment of Drug Discovery" launch event. China Merchants Securities previously pointed out that AI empowers the entire drug discovery platform, evolving from "AI-assisted" to "AI-driven." By the end of 2024, the AIDD platform is expected to have participated in a total of 157 projects, with 51 cumulative clients for CADD/AIDD, and projects empowered by AI generating over ten million dollars in revenue, having already achieved well-known collaborations for a complete set of AI discovery solutions in certain niche areas